Trends in Modern Drug Discovery.
Drugs discovered by the pharmaceutical industry over the past 100 years have dramatically changed the practice of medicine and impacted on many aspects of our culture. For many years, drug discovery was a target- and mechanism-agnostic approach that was based on ethnobotanical knowledge often fueled by serendipity. With the advent of modern molecular biology methods and based on knowledge of the human genome, drug discovery has now largely changed into a hypothesis-driven target-based approach, a development which was paralleled by significant environmental changes in the pharmaceutical industry. Laboratories became increasingly computerized and automated, and geographically dispersed research sites are now more and more clustered into large centers to capture technological and biological synergies. Today, academia, the regulatory agencies, and the pharmaceutical industry all contribute to drug discovery, and, in order to translate the basic science into new medical treatments for unmet medical needs, pharmaceutical companies have to have a critical mass of excellent scientists working in many therapeutic fields, disciplines, and technologies. The imperative for the pharmaceutical industry to discover breakthrough medicines is matched by the increasing numbers of first-in-class drugs approved in recent years and reflects the impact of modern drug discovery approaches, technologies, and genomics.
Novartis Pharma AG, CH-4056, Basel, Switzerland.
Jörg
J
Eder
Novartis Pharma AG, CH-4056, Basel, Switzerland. paul.herrling@novartis.com.
Paul L
PL
Herrling
D055808:Drug Discovery / Q000639:trends*; D015894:Genome, Human; D006801:Humans
Lead discovery; Pharmaceutical industry; Pharmaceutical research; Phenotypic screening; R&D productivity; Target discovery; Target-based drug discovery